Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Insight Molecular Diagnostics (IMDX) Other Operating Expenses (2020 - 2025)

Insight Molecular Diagnostics (IMDX) has disclosed Other Operating Expenses for 6 consecutive years, with $15.8 million as the latest value for Q4 2025.

  • Quarterly Other Operating Expenses fell 46.35% to $15.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $26.9 million through Dec 2025, down 35.58% year-over-year, with the annual reading at $26.9 million for FY2025, 35.58% down from the prior year.
  • Other Operating Expenses hit $15.8 million in Q4 2025 for Insight Molecular Diagnostics, up from $4.8 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $29.4 million in Q4 2024 to a low of -$11.4 million in Q1 2023.
  • Historically, Other Operating Expenses has averaged $4.1 million across 5 years, with a median of $3.7 million in 2021.
  • Biggest five-year swings in Other Operating Expenses: plummeted 330.56% in 2022 and later surged 2495.51% in 2025.
  • Year by year, Other Operating Expenses stood at $9.1 million in 2021, then plummeted by 43.09% to $5.2 million in 2022, then soared by 128.14% to $11.8 million in 2023, then skyrocketed by 149.99% to $29.4 million in 2024, then crashed by 46.35% to $15.8 million in 2025.
  • Business Quant data shows Other Operating Expenses for IMDX at $15.8 million in Q4 2025, $4.8 million in Q3 2025, and $4.3 million in Q2 2025.